Frontiers in Anti-Infective Drug Discovery

Volume 4

by

Atta-ur-Rahman , M. Iqbal Choudhary

DOI: 10.2174/97816810808261150401
eISBN: 978-1-68108-082-6, 2015
ISBN: 978-1-68108-083-3
ISSN: 2451-9162 (Print)
ISSN: 1879-663X (Online)



Recommend this eBook to your Library



This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discov...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

List of Contributors

- Pp. iii-iv (2)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Resistance to FDA Licensed Anti-Neuraminidase Drugs Used for Flu Treatment in the Americas: An Overview of the Incidence of Resistant-Strains of Seasonal and Pandemic Influenza Viruses from 2004 to 2014

- Pp. 3-30 (28)

L.A.M.G. Fornells and J.N.S.S. Couceiro

View Abstract Download Free

Antidepressants Used as Chemotherapy for Trypanosoma cruzi Infection: Phenothiazines and Derivative Compounds

- Pp. 31-67 (37)

Patricia Paglini Oliva, Silvina Lo Presti and Walter Rivarola

View Abstract Purchase Chapter

Polysaccharide Deacetylases: New Antibacterial Drug Targets

- Pp. 68-130 (63)

Stavroula Balomenou, Sofia Arnaouteli, Dimitris Koutsioulis, Vasiliki E. Fadouloglou and Vassilis Bouriotis

View Abstract Purchase Chapter

Targeting RNA with Aminoglycosides: Current Improvements in their Synthesis and Biological Activity

- Pp. 131-209 (79)

Andrés G. Santana, Sandra G. Zárate, Agatha Bastida and Julia Revuelta

View Abstract Purchase Chapter

New Chemotherapeutic Agents against Common Infections: Clinical Studies on New Anti-Infective Agents

- Pp. 210-229 (20)

Ana García-Robles, Virginia Bosó-Ribelles, Eva Romá-Sánchez and José Luis Poveda-Andrés

View Abstract Purchase Chapter

Index

- Pp. 230-238 (9)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

Preface

Infectious diseases continue to be an enduring threat to human survival and well-being. The recent Ebola epidemic in Western Africa has revealed a number of limitations at every front, including lack of timely response, improper disease surveillance, failure of national governments to control epidemics and most importantly, the failure of the pharmaceutical industry to develop a single effective drug for a disease which is known to be so deadly since the last four decades. This is indeed an early warning for other deadlier future epidemics which may soon emerge.

Continuous research on new potent anti-infective drugs, and efforts to understand infections at the molecular level to identify new drug targets are urgently needed. The 4th volume of the eBook series “Frontiers in Anti-Infective Drug Discovery” is therefore timely and important. It is a compilation of five well written chapters, contributed by leading practitioners in the field.

The chapter by Fornells and Couceiro provides details of the emerging resistance against flu treatments with anti-neuraminidase drugs. The presence of mutations in the influenza virus, responsible for producing resistance against anti-neuraminidase drugs, is discussed in detail.

Drug repositioning is an important approach for drug discovery and development. Oliva et al. have conducted extensive studies on the use of the anti-depressant drugs, such as phenothiliazines as anti-trypanosomal drugs. Trypanosoma cruzi is the causative agent of a common parasitic tropical disease, called Chagas disease. These well known anti-depressant drugs exert their trypanocidal effects by inhibiting trypanothione reductase, an enzyme which is essential for the redox defense system of the parasite. This article provides strong support for the drug repositioning / repurposing approach, i.e. for finding new health benefits in old drugs.

Bouriotis et al. have reviewed the current state of research with respect to bacterial polysaccharide deacetylases as drug targets for antibacterial drug development. Polysaccharide deacetylase plays an important role in the bacterial life cycle, and its inhibition is an important approach towards the development of new anti-bacterial drugs.

Revuelta et al. present a review on the potential of RNA-binding drugs as anti-infectious agents. They describe the use of positively charged aminoglycoside class of compounds that bind with ribosomal RNA, and can serve as anti-bacterial agents. These compounds can also be used as antiviral drugs against other diseases.

Finally, Boso-Ribelles et al. have contributed a comprehensive review on the changing landscape of antibiotic development, which does not seem very promising. They summarize the outcomes of several drug discovery initiatives, new antibiotics in the pipeline, and current state of research on old drugs to develop new antibiotics. This chapter, in brief, is a charge sheet on the negligence towards this important field, which is now causing tremendous human suffering.

This volume is the result of hard work of many eminent researchers. We wish to express our profound gratitude to them. We would also like to acknowledge the dedication and hard work of the excellent team of Bentham Science Publishers, led by Mr. Mahmood Alam, Director of Bentham Science Publishers. The efforts of Ms. Fariya Zulfiqar, Assistant Manager Publications, deserve special appreciation.

Prof. Atta-ur-Rahman, FRS

Honorary Life Fellow
Kings College
University of Cambridge
UK

Prof. M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Pakistan

List of Contributors

Editor(s):
Atta-ur-Rahman
University of Cambridge
Kings College
Cambridge
UK


M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
University of Karachi
Karachi, 75270
Pakistan




Contributor(s):
Agatha Bastida
Institute of General Organic Chemistry of the Spanish National Research Council
Bioorganic Chemistry Department
Juan de la Cierva, 3, 28006-Madrid
Spain


Ana García-Robles
Pharmacy Department
Hospital Universitari i Politècnic La Fe
Valencia
Spain


Andrés G. Santana
Institute of General Organic Chemistry of the Spanish National Research Council
Bioorganic Chemistry Department
Juan de la Cierva, 3, 28006-Madrid
Spain


Dimitris Koutsioulis
Department of Biology, Enzyme Biotechnology Group
University of Crete
P.O. Box 2208, Vasilika Vouton
Heraklion
Crete, 714 09
Greece


Eva Romá-Sánchez
Pharmacy Department
Hospital Universitari i Politècnic La Fe
Valencia
Spain


J.N.S.S. Couceiro
Institute of Microbiology Paulo de Góes
Federal University of Rio de Janeiro
Rio de Janeiro
RJ, 21941-902
Brazil


José Luis Poveda-Andrés
Pharmacy Department
Hospital Universitari i Politècnic La Fe
Valencia
Spain


Julia Revuelta
Institute of General Organic Chemistry of the Spanish National Research Council
Bioorganic Chemistry Department
Juan de la Cierva, 3, 28006-Madrid
Spain


L.A.M.G. Fornells
Institute of Microbiology Paulo de Góes
Federal University of Rio de Janeiro
Rio de Janeiro
RJ, 21941-902
Brazil


Patricia Paglini Oliva
Medical Biophysics, Faculty of Medicine and INICSA
CONICET, National University of Córdoba
Santa Rosa
Córdoba, 1085
Argentina


Sandra G. Zárate
Institute of General Organic Chemistry of the Spanish National Research Council
Bioorganic Chemistry Department
Juan de la Cierva, 3, 28006-Madrid
Spain


Silvina Lo Presti
Medical Biophysics, Faculty of Medicine and INICSA
CONICET, National University of Córdoba
Santa Rosa
Córdoba, 1085
Argentina


Sofia Arnaouteli
Department of Biology, Enzyme Biotechnology Group
University of Crete
P.O. Box 2208, Vasilika Vouton
Heraklion
Crete, 714 09
Greece


Stavroula Balomenou
Institute of Molecular Biology and Biotechnology
Heraklion
Crete, 70013
Greece
/
Department of Biology, Enzyme Biotechnology Group
University of Crete
P.O. Box 2208, Vasilika Vouton
Heraklion
Crete, 714 09
Greece


Vasiliki E. Fadouloglou
Institute of Molecular Biology and Biotechnology
Heraklion
Crete, 70013
Greece


Vassilis Bouriotis
Institute of Molecular Biology and Biotechnology
Heraklion
Crete, 70013
Greece
/
Department of Biology, Enzyme Biotechnology Group
University of Crete
P.O. Box 2208, Vasilika Vouton
Heraklion
Crete, 714 09
Greece


Virginia Bosó-Ribelles
Pharmacy Department
Hospital Universitari i Politècnic La Fe
Valencia
Spain


Walter Rivarola
Medical Biophysics, Faculty of Medicine and INICSA, CONICET
National University of Córdoba
Córdoba
Santa Rosa, 1085
Argentina




Advertisement

Pharmaceutical Microbiology USAFraunhofer Life Science Symposium Leipzig


Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science